Acadia is making the best of it, but their latest PhIII Nuplazid study is a bust
Acadia’s late-stage program to widen the commercial prospects for Nuplazid has hit a wall. The biotech reported that their Phase III ENHANCE trial flat failed. And while they $ACAD did their best to cherry pick positive data wherever they can be found, this is a clear setback for the biotech.
With close to 400 patients enrolled, researchers said the drug flunked the primary endpoint as an adjunctive therapy for patients with an inadequate response to antipsychotic therapy. The p-value was an ugly 0.0940 on the Positive and Negative Syndrome Scale, which the company called out as a positive trend.
Their shares slid 12% on the news, good for a $426 million hit on a $3.7 billion market cap at close.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 85,300+ biopharma pros reading Endpoints daily — and it's free.